Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ovulation product cycles to FTC, FDA

This article was originally published in The Tan Sheet

Executive Summary

Advertising for Ovulex Fertility Enhancement has been referred to FTC and FDA after AMI, Inc/Selmedica Healthcare declined to participate in NAD's self-regulatory forum, watchdog group says Dec. 6. NAD was troubled by claims that the product will "increase your chances of conception by 1870% in less than 10 days," and "women who use the Ovulex plan are up to 1800% more likely to conceive," which were found during the group's routine monitoring program...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS097622

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel